patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_654712 | REC_0014001 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 16.6 | 76 | female | 1 | 11 | 6.9 | 5 | sotorasib 960 mg daily | 10.6 | true | MSI-H | 2026-03-15T05:36:00.611750+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_225253 | REC_0014002 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 16.5 | 72 | female | 1 | 6 | 6 | 6 | entrectinib 600 mg daily | 5.5 | true | MSI-H | 2026-03-15T05:36:00.612276+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_214127 | REC_0014003 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 9.9 | 66 | male | 1 | 20 | 6.2 | 1 | osimertinib 80 mg daily | 20.3 | false | MSS | 2026-03-15T05:36:00.612700+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_660624 | REC_0014004 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 10.8 | 57 | male | 1 | 12 | 4.8 | 5 | sotorasib 960 mg daily | 15.5 | false | MSS | 2026-03-15T05:36:00.613061+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_967134 | REC_0014005 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 15.6 | 82 | female | 2 | 14 | 5.2 | 7 | sotorasib 960 mg daily | 7.2 | false | MSS | 2026-03-15T05:36:00.613415+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_304562 | REC_0014006 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 11.2 | 60 | male | 1 | 13 | 4.7 | 3 | sotorasib 960 mg daily | 24.6 | true | MSI-H | 2026-03-15T05:36:00.613965+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_652455 | REC_0014007 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 15.3 | 56 | female | 1 | 26 | 6.2 | 2 | pembrolizumab 200 mg q3w | 13.5 | false | MSS | 2026-03-15T05:36:00.614388+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_186499 | REC_0014008 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 13.5 | 58 | male | 0 | 15 | 4.2 | 2 | sotorasib 960 mg daily | 16.2 | false | MSS | 2026-03-15T05:36:00.614710+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_507134 | REC_0014009 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 11 | 64 | female | 0 | 4 | 4 | 5 | alectinib 600 mg BID | 7.6 | false | MSS | 2026-03-15T05:36:00.615058+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_777441 | REC_0014010 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 8.1 | 70 | female | 1 | 20 | 4.9 | 1 | alectinib 600 mg BID | 22.2 | true | MSS | 2026-03-15T05:36:00.615468+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_480410 | REC_0014011 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 17.3 | 76 | male | 1 | 9 | 3 | 6 | alectinib 600 mg BID | 15.9 | false | MSI-H | 2026-03-15T05:36:00.615826+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_804068 | REC_0014012 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 19.2 | 77 | female | 2 | 9 | 6 | 6 | alectinib 600 mg BID | 4 | false | MSI-H | 2026-03-15T05:36:00.616227+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_593970 | REC_0014013 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 5.6 | 57 | female | 1 | 20 | 7.2 | 4 | alectinib 600 mg BID | 10.1 | true | MSS | 2026-03-15T05:36:00.616578+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_308112 | REC_0014014 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 9.9 | 81 | female | 1 | 23 | 7.3 | 0 | osimertinib 80 mg daily | 13 | true | MSS | 2026-03-15T05:36:00.616907+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_231138 | REC_0014015 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 13.9 | 65 | female | 0 | 13 | 7.4 | 5 | alectinib 600 mg BID | 17.9 | true | MSI-H | 2026-03-15T05:36:00.617419+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_798558 | REC_0014016 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 12.2 | 73 | female | 1 | 13 | 4.5 | 5 | entrectinib 600 mg daily | 13 | false | MSS | 2026-03-15T05:36:00.617826+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_106693 | REC_0014017 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 16 | 4.4 | 45 | female | 0 | 20 | 4.2 | 0 | entrectinib 600 mg daily | 22.2 | true | MSS | 2026-03-15T05:36:00.618208+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_936399 | REC_0014018 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 30 | 7 | 56 | male | 0 | 42 | 4.6 | 0 | carboplatin + paclitaxel + pembrolizumab | 38.7 | true | MSS | 2026-03-15T05:36:00.618562+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_967913 | REC_0014019 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 22 | 5.2 | 63 | male | 1 | 17 | 5.2 | 2 | pembrolizumab 200 mg q3w | 17.3 | false | MSS | 2026-03-15T05:36:00.618885+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_115200 | REC_0014020 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 3.6 | 74 | female | 1 | 31 | 3.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 20.8 | true | MSS | 2026-03-15T05:36:00.619301+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_423255 | REC_0014021 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 19 | 6.2 | 71 | female | 1 | 61 | 6.7 | 1 | pembrolizumab 200 mg q3w | 18.4 | true | MSS | 2026-03-15T05:36:00.619697+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_185241 | REC_0014022 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 12.3 | 61 | female | 0 | 20 | 5.4 | 1 | sotorasib 960 mg daily | 25.8 | true | MSI-H | 2026-03-15T05:36:00.620071+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_720115 | REC_0014023 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 13 | 73 | female | 1 | 14 | 4.3 | 3 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:36:00.620505+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_290073 | REC_0014024 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 12.9 | 65 | female | 0 | 20 | 5.1 | 5 | alectinib 600 mg BID | 13 | false | MSI-H | 2026-03-15T05:36:00.620877+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_398537 | REC_0014025 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 9.4 | 60 | female | 1 | 13 | 6.2 | 3 | entrectinib 600 mg daily | 13.7 | true | MSS | 2026-03-15T05:36:00.621211+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_832938 | REC_0014026 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 14.8 | 72 | female | 1 | 14 | 6.3 | 2 | sotorasib 960 mg daily | 14.9 | true | MSS | 2026-03-15T05:36:00.621545+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_424840 | REC_0014027 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 10 | 70 | female | 2 | 37 | 5.6 | 7 | pembrolizumab 200 mg q3w | 17.6 | false | MSS | 2026-03-15T05:36:00.621867+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_614745 | REC_0014028 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 11.4 | 75 | female | 1 | 8 | 6.3 | 7 | entrectinib 600 mg daily | 12.8 | true | MSI-H | 2026-03-15T05:36:00.622343+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_404191 | REC_0014029 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 14.5 | 64 | female | 1 | 18 | 5.5 | 5 | sotorasib 960 mg daily | 10.9 | false | MSI-H | 2026-03-15T05:36:00.622700+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_806133 | REC_0014030 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 30 | 3.6 | 64 | female | 1 | 3 | 6.5 | 3 | pembrolizumab 200 mg q3w | 10.2 | false | MSS | 2026-03-15T05:36:00.623019+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_339159 | REC_0014031 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 10.8 | 71 | female | 3 | 14 | 5.3 | 4 | sotorasib 960 mg daily | 9.7 | false | MSS | 2026-03-15T05:36:00.623320+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_374851 | REC_0014032 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 9.6 | 64 | male | 0 | 6 | 8 | 8 | entrectinib 600 mg daily | 5.8 | true | MSS | 2026-03-15T05:36:00.623601+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_873545 | REC_0014033 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 16.3 | 58 | female | 0 | 7 | 7.8 | 6 | sotorasib 960 mg daily | 18.9 | false | MSS | 2026-03-15T05:36:00.623866+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_974449 | REC_0014034 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 8.6 | 79 | male | 1 | 22 | 6.4 | 7 | pembrolizumab 200 mg q3w | 14.5 | false | MSS | 2026-03-15T05:36:00.624197+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_226513 | REC_0014035 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 9.7 | 73 | female | 1 | 3 | 6.3 | 5 | sotorasib 960 mg daily | 6 | true | MSS | 2026-03-15T05:36:00.624491+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_538998 | REC_0014036 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 32 | 7.4 | 73 | female | 1 | 11 | 6.7 | 4 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:36:00.624778+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_293395 | REC_0014037 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 23 | 5.8 | 68 | female | 1 | 14 | 6.8 | 0 | osimertinib 80 mg daily | 60.9 | true | MSS | 2026-03-15T05:36:00.625076+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_579753 | REC_0014038 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 6.4 | 78 | female | 1 | 40 | 5.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.1 | true | MSS | 2026-03-15T05:36:00.625380+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_159977 | REC_0014039 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 13.7 | 67 | female | 0 | 16 | 5.8 | 3 | osimertinib 80 mg daily | 11 | true | MSI-H | 2026-03-15T05:36:00.625668+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_298966 | REC_0014040 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 16.9 | 69 | male | 0 | 19 | 5.9 | 6 | osimertinib 80 mg daily | 14.5 | true | MSI-H | 2026-03-15T05:36:00.625961+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_264781 | REC_0014041 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 8.8 | 78 | female | 2 | 23 | 5 | 7 | osimertinib 80 mg daily | 7.9 | false | MSS | 2026-03-15T05:36:00.626431+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_536394 | REC_0014042 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 12.5 | 78 | female | 2 | 18 | 4.3 | 4 | osimertinib 80 mg daily | 9 | false | MSI-H | 2026-03-15T05:36:00.626757+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_460788 | REC_0014043 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 4.5 | 69 | male | 0 | 63 | 6.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 12.9 | false | MSS | 2026-03-15T05:36:00.627068+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_743820 | REC_0014044 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 6.6 | 76 | female | 1 | 22 | 3.6 | 2 | entrectinib 600 mg daily | 23.7 | true | MSS | 2026-03-15T05:36:00.627365+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_166840 | REC_0014045 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 12.9 | 71 | female | 2 | 2 | 6.2 | 7 | alectinib 600 mg BID | 9.2 | false | MSS | 2026-03-15T05:36:00.627657+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_772575 | REC_0014046 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 14.2 | 58 | female | 0 | 7 | 5.1 | 6 | alectinib 600 mg BID | 13.7 | true | MSS | 2026-03-15T05:36:00.627960+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_118182 | REC_0014047 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 5.8 | 65 | female | 1 | 99 | 4.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.7 | false | MSS | 2026-03-15T05:36:00.628363+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_540831 | REC_0014048 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 6.8 | 86 | female | 1 | 19 | 4.7 | 6 | pembrolizumab 200 mg q3w | 10.3 | false | MSS | 2026-03-15T05:36:00.628704+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_498656 | REC_0014049 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 13.6 | 53 | female | 0 | 28 | 3.8 | 10 | sotorasib 960 mg daily | 7.7 | true | MSS | 2026-03-15T05:36:00.629042+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_914117 | REC_0014050 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 12.8 | 81 | female | 2 | 8 | 3.7 | 3 | osimertinib 80 mg daily | 13.5 | true | MSI-H | 2026-03-15T05:36:00.629383+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_372416 | REC_0014051 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.7 | 67 | female | 1 | 62 | 6.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 6.3 | false | MSS | 2026-03-15T05:36:00.629720+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_259198 | REC_0014052 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 13 | 63 | male | 0 | 9 | 5.7 | 9 | osimertinib 80 mg daily | 9.6 | false | MSS | 2026-03-15T05:36:00.630066+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_121037 | REC_0014053 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 29 | 4.9 | 89 | male | 2 | 7 | 3.8 | 1 | pembrolizumab 200 mg q3w | 25.6 | false | MSS | 2026-03-15T05:36:00.630382+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_264794 | REC_0014054 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 12.9 | 49 | female | 0 | 14 | 6.7 | 8 | sotorasib 960 mg daily | 14.2 | false | MSS | 2026-03-15T05:36:00.630915+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356910 | REC_0014055 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 10 | 63 | female | 1 | 15 | 5.7 | 1 | osimertinib 80 mg daily | 17.1 | true | MSS | 2026-03-15T05:36:00.631302+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_459602 | REC_0014056 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 16.3 | 85 | female | 2 | 9 | 6.5 | 6 | entrectinib 600 mg daily | 10.3 | false | MSS | 2026-03-15T05:36:00.631664+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_329332 | REC_0014057 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 6.3 | 81 | female | 2 | 10 | 5.2 | 6 | entrectinib 600 mg daily | 13.3 | true | MSS | 2026-03-15T05:36:00.632057+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_236744 | REC_0014058 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 3 | 75 | male | 2 | 51 | 7.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 21.8 | false | MSS | 2026-03-15T05:36:00.633328+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322910 | REC_0014059 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 7.1 | 68 | female | 0 | 15 | 3.7 | 7 | osimertinib 80 mg daily | 14.3 | false | MSS | 2026-03-15T05:36:00.633668+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_161689 | REC_0014060 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 15.2 | 70 | female | 1 | 11 | 6.6 | 6 | osimertinib 80 mg daily | 14.3 | true | MSI-H | 2026-03-15T05:36:00.633967+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_434658 | REC_0014061 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.9 | 68 | female | 0 | 36 | 5.2 | 7 | carboplatin + paclitaxel + pembrolizumab | 14.4 | true | MSS | 2026-03-15T05:36:00.634283+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_605954 | REC_0014062 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 11.6 | 58 | male | 0 | 22 | 5.4 | 4 | osimertinib 80 mg daily | 15.5 | false | MSI-H | 2026-03-15T05:36:00.634658+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_266968 | REC_0014063 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 17.3 | 75 | female | 1 | 3 | 3.8 | 8 | entrectinib 600 mg daily | 16.5 | true | MSS | 2026-03-15T05:36:00.634992+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_656832 | REC_0014064 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 13.6 | 65 | male | 1 | 6 | 5.2 | 1 | osimertinib 80 mg daily | 28 | true | MSS | 2026-03-15T05:36:00.635288+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_454507 | REC_0014065 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 8.7 | 52 | male | 0 | 20 | 5.1 | 7 | entrectinib 600 mg daily | 20.1 | false | MSS | 2026-03-15T05:36:00.635581+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_143519 | REC_0014066 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6.5 | 49 | male | 0 | 44 | 4.9 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.2 | false | MSS | 2026-03-15T05:36:00.635874+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_487453 | REC_0014067 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 3.3 | 76 | female | 2 | 74 | 5.2 | 7 | carboplatin + paclitaxel + pembrolizumab | 6.7 | false | MSS | 2026-03-15T05:36:00.636383+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_258449 | REC_0014068 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 9.3 | 65 | female | 0 | 7 | 4 | 5 | osimertinib 80 mg daily | 5.8 | true | MSS | 2026-03-15T05:36:00.636706+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_345887 | REC_0014069 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 33 | 8.5 | 56 | female | 1 | 15 | 6.1 | 1 | pembrolizumab 200 mg q3w | 13.8 | true | MSS | 2026-03-15T05:36:00.636994+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_420820 | REC_0014070 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 6.5 | 76 | female | 2 | 57 | 5.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.8 | true | MSS | 2026-03-15T05:36:00.637272+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_228981 | REC_0014071 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 7.1 | 67 | female | 1 | 11 | 5.9 | 5 | pembrolizumab 200 mg q3w | 10.5 | true | MSS | 2026-03-15T05:36:00.637545+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_960272 | REC_0014072 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 11.8 | 67 | female | 0 | 18 | 4.7 | 4 | osimertinib 80 mg daily | 13.2 | true | MSI-H | 2026-03-15T05:36:00.637823+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_510372 | REC_0014073 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 6.2 | 69 | female | 0 | 20 | 5.2 | 6 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:36:00.638104+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165185 | REC_0014074 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 16.4 | 61 | male | 1 | 27 | 5.8 | 2 | osimertinib 80 mg daily | 9.7 | false | MSI-H | 2026-03-15T05:36:00.638388+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_481114 | REC_0014075 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 16 | 14 | 65 | female | 1 | 12 | 3.6 | 6 | osimertinib 80 mg daily | 10 | false | MSS | 2026-03-15T05:36:00.638674+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_370510 | REC_0014076 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 13 | 14.4 | 71 | male | 1 | 15 | 5.6 | 6 | sotorasib 960 mg daily | 15.4 | true | MSI-H | 2026-03-15T05:36:00.638958+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_509684 | REC_0014077 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 8.1 | 50 | male | 0 | 11 | 5.5 | 2 | osimertinib 80 mg daily | 25.1 | true | MSS | 2026-03-15T05:36:00.639250+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_122701 | REC_0014078 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 11.8 | 58 | male | 1 | 23 | 3.8 | 2 | osimertinib 80 mg daily | 25.4 | false | MSI-H | 2026-03-15T05:36:00.639541+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_376564 | REC_0014079 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 15.2 | 76 | female | 1 | 16 | 5.7 | 2 | entrectinib 600 mg daily | 24.2 | true | MSI-H | 2026-03-15T05:36:00.639841+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_771436 | REC_0014080 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 6.9 | 81 | female | 1 | 7 | 4.7 | 2 | osimertinib 80 mg daily | 20 | false | MSS | 2026-03-15T05:36:00.640326+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_395036 | REC_0014081 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 11 | 63 | female | 1 | 15 | 7.2 | 1 | entrectinib 600 mg daily | 18.6 | true | MSI-H | 2026-03-15T05:36:00.640673+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_497099 | REC_0014082 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 8.9 | 64 | female | 1 | 20 | 4.8 | 6 | osimertinib 80 mg daily | 11.5 | false | MSS | 2026-03-15T05:36:00.640986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_291133 | REC_0014083 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 28 | 19.7 | 64 | female | 1 | 18 | 5.5 | 0 | alectinib 600 mg BID | 26.3 | false | MSI-H | 2026-03-15T05:36:00.641290+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_281950 | REC_0014084 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 4.9 | 71 | female | 1 | 45 | 4.2 | 4 | carboplatin + paclitaxel + pembrolizumab | 7.7 | true | MSS | 2026-03-15T05:36:00.641586+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_654586 | REC_0014085 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 5 | 53 | male | 0 | 15 | 7 | 7 | sotorasib 960 mg daily | 15.1 | false | MSS | 2026-03-15T05:36:00.641892+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_627715 | REC_0014086 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 4.8 | 66 | female | 0 | 54 | 6 | 3 | carboplatin + paclitaxel + pembrolizumab | 10.8 | true | MSS | 2026-03-15T05:36:00.642209+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_368547 | REC_0014087 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 11.2 | 67 | female | 0 | 0 | 5.1 | 1 | entrectinib 600 mg daily | 11.2 | false | MSS | 2026-03-15T05:36:00.642552+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_208433 | REC_0014088 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 7.8 | 62 | male | 0 | 49 | 6.9 | 0 | carboplatin + paclitaxel + pembrolizumab | 15.7 | false | MSS | 2026-03-15T05:36:00.642891+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_735301 | REC_0014089 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 7.8 | 75 | female | 0 | 12 | 3.9 | 2 | entrectinib 600 mg daily | 10.9 | false | MSS | 2026-03-15T05:36:00.643243+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_543700 | REC_0014090 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 12.8 | 54 | male | 0 | 15 | 6.9 | 4 | sotorasib 960 mg daily | 13.6 | false | MSS | 2026-03-15T05:36:00.643582+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_126989 | REC_0014091 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 6.7 | 55 | female | 0 | 27 | 6.9 | 5 | pembrolizumab 200 mg q3w | 8.7 | true | MSS | 2026-03-15T05:36:00.643900+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_761961 | REC_0014092 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 13.9 | 66 | female | 1 | 21 | 4.2 | 6 | osimertinib 80 mg daily | 10.4 | true | MSS | 2026-03-15T05:36:00.644307+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_189462 | REC_0014093 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 9.7 | 65 | male | 1 | 3 | 6.4 | 6 | pembrolizumab 200 mg q3w | 13 | false | MSS | 2026-03-15T05:36:00.644823+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_820527 | REC_0014094 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 16.6 | 61 | female | 1 | 9 | 6.7 | 4 | alectinib 600 mg BID | 8.7 | false | MSS | 2026-03-15T05:36:00.645230+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_697847 | REC_0014095 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 14.5 | 60 | female | 0 | 7 | 5.3 | 5 | entrectinib 600 mg daily | 11.9 | false | MSS | 2026-03-15T05:36:00.645571+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_180334 | REC_0014096 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 13.8 | 81 | female | 1 | 10 | 3.6 | 1 | sotorasib 960 mg daily | 14.2 | true | MSS | 2026-03-15T05:36:00.645921+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_345169 | REC_0014097 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 8 | 63 | female | 0 | 7 | 5.6 | 2 | sotorasib 960 mg daily | 14.2 | false | MSS | 2026-03-15T05:36:00.646231+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_152850 | REC_0014098 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 16.1 | 89 | male | 2 | 20 | 5.3 | 1 | osimertinib 80 mg daily | 22.4 | false | MSI-H | 2026-03-15T05:36:00.646567+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_192760 | REC_0014099 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 12 | 66 | female | 1 | 10 | 5.5 | 4 | osimertinib 80 mg daily | 11 | true | MSI-H | 2026-03-15T05:36:00.646910+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_842902 | REC_0014100 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 10.5 | 61 | female | 1 | 11 | 6.7 | 2 | osimertinib 80 mg daily | 10.9 | false | MSS | 2026-03-15T05:36:00.647241+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.